Stockreport

Recursion Pharmaceuticals: Artificial Intelligence, Real Disappointment [Seeking Alpha]

Recursion Pharmaceuticals, Inc. - Class A  (RXRX) 
PDF REC-4881's Phase 1/2 data show a median polyp reduction of 43%, but mean efficacy matches Celebrex, undermining premium pricing or clinical differentiation. Durabilit [Read more]